EOM Pharmaceutical Holdings Reports FDA Clearance of an IND for a Clinical Trial in Cachectic Cancer Patients

EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) (“EOM”, the “Company”) an innovative clinical-stage biotechnology company focused on developing transformative treatments for chronic inflammatory ...
Medical Xpress

Weight loss in cancer: Organs respond to the disease in a coordinated way, study finds

Cachexia is a metabolic disorder that causes uncontrolled weight loss and muscle wasting in chronic diseases and cancer. A new study by Helmholtz Munich, in collaboration with the Institute of ...
Nasdaq

Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care

Case involving senior dosimetrist at a premier cancer hospital in the Northeast suggests potential relevance of Phyto-N in one of oncology’s most serious and underserved supportive-care markets The ...
EurekAlert!

Weight loss in cancer: Organs respond to the disease in a coordinated way

Cachexia is a metabolic disorder that causes uncontrolled weight loss and muscle wasting in chronic diseases and cancer. A new study by Helmholtz Munich, in collaboration with the Institute of ...